Immunogenicity and Safety of Booster Dose of S-268019-b or Tozinameran in Japanese Participants: An Interim Report of Phase 2/3, Randomized, Observer-Blinded, Noninferiority Study
bioRxiv (2022) - Comments
doi: 10.1101/2022.03.03.22271827 

Masaharu Shinkai, Takuhiro Sonoyama, Akari Kamitani, Risa Shibata, Naomi Seki, Shinya Omoto, Masahiro Shinoda, Takashi Sato, Naoki Ishii, Kenji Igarashi, Mari Ariyasu